Korean J Med > Volume 72(5); 2007 > Article
The Korean Journal of Medicine 2007;72(5):459-469.
Non-invasive assessment of liver fibrosis by measuring the liver stiffness and biochemical markers in chronic hepatitis B patients
Hwa Sook Kim, Ja Kyung Kim, Young Nyun Park, Sung Min Myung, Mi Sun Pang, Ki Tae Youn, Keun Ho Lee, Yong Han Paik, Kwan Sik Lee, Sang Hoon Ahn, Chae Yoon Chon, Young Myoung Moon, Kwang Hyub Han
고려대학교 의과대학 내과학교실
원저 : 만성 B형 간염환자에서 간탄력도 측정에 의한 간섬유화의 비침습적 평가
김화숙, Ja Kyung Kim, Young Nyun Park, Sung Min Myung, Mi Sun Pang, Ki Tae Youn, Keun Ho Lee, Yong Han Paik, Kwan Sik Lee, Sang Hoon Ahn, Chae Yoon Chon, Young Myoung Moon, Kwang Hyub Han
Abstract
Background : Transient elastography (FibroScanⓇ) is a rapid and non-invasive method to measure liver stiffness and this allow the assessment of liver fibrosis. The aim of this study was to assess the diagnostic accuracy of measuring the liver stiffness in addition to measuring the other biochemical markers such as the aspartate transaminase to platelet ratio index [APRI] and the AST/ALT ratio.
Methods
: We enrolled 228 HBsAg positive patients whose liver stiffness was measured by FibroScanⓇ between March 2005 and September 2005. Liver biopsy examinations were performed in 34 patients. The fibrosis (F) was staged on a 0-4 scale according to the Ludwig classification.
Results
: According to the clinical diagnosis, the median values of liver stiffness were 7.0±2.7 kPa for inactive carriers (n=29), 8.3±5.3 kPa for chronic hepatitis patients (n=106), 15.9±8.3 kPa for compensated cirrhosis patients (n=63), 31.8±20.3 kPa for decompensated cirrhosis patients (n=26), and 45.1±34.5 kPa for HCC patients (n=4). The degree of liver stiffness was significantly different between the different disease groups (p<0.001). Liver stiffness was well correlated with the fibrosis stages (r=0.726; p< 0.001). The AUROC of FibroScanⓇ, the APRI and the AST/ALT ratio values were of the same order; 0.72, 0.61 and 0.58, respectively, for F≥2; 0.92, 0.73, and 0.56, respectively, for F≥3; and 0.97, 0.79, and 0.55, respectively, for F=4. FibroScanⓇ offered the best diagnostic performance both for significant fibrosis (F≥2) and severe fibrosis-cirrhosis (F3-F4).
Conclusions
: FibroScanⓇ is a reliable, rapid non-invasive method to diagnose the severity of chronic liver disease and to predict fibrosis in patients with chronic hepatitis B, in addition to using the APRI and AST/ALT ratio.(Korean J Med 72:459-469, 2007) Key Words : Hepatitis B, Liver fibrosis, Non-invasive, Diagnosis, Liver stiffness
Key Words: Hepatitis B, Liver fibrosis, Non-invasive, Diagnosis, Liver stiffness


TOOLS
METRICS Graph View
  • 1,624 View
  • 21 Download

Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791    Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr                

Copyright © 2024 by The Korean Association of Internal Medicine.

Developed in M2PI

Close layer
prev next